Zydus Lifesciences has been granted a patent for a pharmaceutical composition in oral suspension form. The composition includes mycophenolate mofetil, xanthan gum, glycerin, sorbitol, preservatives, flavoring agents, and other excipients. This invention aims to improve stability, palatability, and ease of administration for immunosuppressive agents. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Zydus Lifesciences Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of February 2024 was 71%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11918684B2) discloses a pharmaceutical composition comprising specific ingredients in precise concentrations. The composition includes mycophenolate mofetil, xanthan gum, glycerin, sorbitol, sodium methylparaben, sodium propylparaben, simethicone, polysorbate 80, NaH2PO4 dihydrate, Na2HPO4 dihydrate, a flavoring agent, and water. The flavoring agent can be an essential oil or a fruit flavor, enhancing the palatability of the composition.

The patent also outlines a detailed process for preparing the pharmaceutical composition. The process involves sequential steps such as mixing water with phosphates, glycerin, polysorbate 80, simethicone, mycophenolate mofetil, xanthan gum, preservatives, sorbitol, and flavoring agent to obtain the final pharmaceutical composition. By following this method, the composition with the specified ingredients and concentrations can be effectively formulated. This patent provides a clear and reproducible method for preparing a pharmaceutical composition with mycophenolate mofetil, catering to potential applications in the medical field.

To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies